Being patient: what delays access to new drugs in Europe?
On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.
Related
Switching tracks: the regulatory implications of Great British Railways—part 2
In this two-part series, we delve into the regulatory implications of rail reform. This reform will bring significant changes to the industry’s structure, including the nationalisation of private passenger train operations and the creation of Great British Railways (GBR)—a vertically integrated body that will manage both track and operations for… Read More
Cost–benefit analyses for public policy
Cost–benefit analyses (CBA) are commonly applied to public infrastructure projects where there is a degree of certainty about the physical output of the project and the consequent societal benefits. CBA can also be applied to proposed policy and regulatory changes, but there is less clarity about the outcomes and the… Read More